ORBi: De Hert Marc - Oral glucose tolerance tests in schizophrenic patients treated with antipsychotics

Reference : Oral glucose tolerance tests in schizophrenic patients treated with antipsychotics


	Document type :	Scientific congresses and symposiums : Paper published in a journal
	Discipline(s) :	Social & behavioral sciences, psychology : Neurosciences & behavior Human health sciences : Neurology
	To cite this reference:	http://hdl.handle.net/2268/2265

Title :	Oral glucose tolerance tests in schizophrenic patients treated with antipsychotics
Language :	English
Author, co-author :	De Hert, Marc [> > > >]
	Van Eyck, Dominique [> > > >]
	Hermans, Gilberte [Centre Hospitalier Universitaire de Liège - CHU > > Anatomie pathologique >]
	Peuskens, Hendrik [> > > >]
	Wampers, Martien [> > > >]
	de Patoul, A. [> > > >]
	Hanssens, L. [> > > >]
	Scheen, André [Université de Liège - ULg > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale]
	Peuskens, Jozef [> > > >]
Publication date :	Jun-2004
Journal title :	International Journal of Neuropsychopharmacology
Publisher :	Cambridge Univ Press
Volume :	7
Issue/season :	Suppl. 1
Pages :	S424
ISSN :	1461-1457
City :	New York
Keywords :	[en] Schizophrenia ; Diabetes ; Metabolic syndrome; ; Antipsychotics
Abstract :	[en] Objective. –A recent consensus conference has proposed guidelines for the monitoring for diabetes in patients with schizophrenia and also identifies the need of long-term prospective studies. Method. – A large scale prospective study on metabolic risks of antipsychotic medication is currently ongoing. At baseline, patients get a full laboratory screening, ECG and an oral glucose tolerance test (OGTT). Baseline data on 100 non-diabetic patients at study inclusion and stable on medication for at least 6 months are presented. Results. – Glucose abnormalities are found in 22% of patients at baseline.A monitoring protocol based only on fasting glucose would not have detected 63.6% of these patients with classifiable glucose abnormalities in our sample. Fasting insulin and measures for insulin resistance have a high predictive value for abnormalities late in the OGTT. Conclusion. – Already at baseline, metabolic problems are frequently present in patients with schizophrenia treated with antipsychotics. Adding assessment of fasting insulin in a monitoring protocol improves detection of glucose abnormalities late in an OGTT.
Target :	Researchers ; Professionals ; Students
Permalink :	http://hdl.handle.net/2268/2265
Other URL :	http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6VM1-4H0S1C8-8-1&_cdi=6137&_user=532038&_orig=search&_coverDate=06%2F30%2F2006&_sk=999789995&view=c&wchp=dGLzVlz-zSkWA&md5=b13936f03d6b2b50a75bfe54187e35ee&ie=/sdarticle.pdf
Commentary :	© 2005 Elsevier SAS. All rights reserved.

File(s) associated to this reference

Fulltext file(s):

	File	Commentary	Version	Size	Access
Open access	de hert ogtt 200 bl European Psychiatry June 2006 21(4)224-6 de hert et al.pdf	No commentary	Publisher postprint	86.32 kB	View/Open

All documents in ORBi are protected by a user license.

Dspace v1.5